341 related articles for article (PubMed ID: 31077261)
1. Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice.
de Retana SF; Marazuela P; Solé M; Colell G; Bonaterra A; Sánchez-Quesada JL; Montaner J; Maspoch D; Cano-Sarabia M; Hernández-Guillamon M
Alzheimers Res Ther; 2019 May; 11(1):42. PubMed ID: 31077261
[TBL] [Abstract][Full Text] [Related]
2. Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis.
Fernández-de-Retana S; Cano-Sarabia M; Marazuela P; Sánchez-Quesada JL; Garcia-Leon A; Montañola A; Montaner J; Maspoch D; Hernández-Guillamon M
Sci Rep; 2017 Nov; 7(1):14637. PubMed ID: 29116115
[TBL] [Abstract][Full Text] [Related]
3. Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.
Miners JS; Clarke P; Love S
Brain Pathol; 2017 May; 27(3):305-313. PubMed ID: 27248362
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Amyloid-β1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier.
Merino-Zamorano C; Fernández-de Retana S; Montañola A; Batlle A; Saint-Pol J; Mysiorek C; Gosselet F; Montaner J; Hernández-Guillamon M
J Alzheimers Dis; 2016 May; 53(2):677-91. PubMed ID: 27232214
[TBL] [Abstract][Full Text] [Related]
5. Regulatory effects of simvastatin and apoJ on APP processing and amyloid-β clearance in blood-brain barrier endothelial cells.
Zandl-Lang M; Fanaee-Danesh E; Sun Y; Albrecher NM; Gali CC; Čančar I; Kober A; Tam-Amersdorfer C; Stracke A; Storck SM; Saeed A; Stefulj J; Pietrzik CU; Wilson MR; Björkhem I; Panzenboeck U
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jan; 1863(1):40-60. PubMed ID: 28941799
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of apoE and apoJ mimetic peptides on the action of an anti-Aβ scFv in 3xTg-AD mice.
Montoliu-Gaya L; Güell-Bosch J; Esquerda-Canals G; Roda AR; Serra-Mir G; Lope-Piedrafita S; Sánchez-Quesada JL; Villegas S
Biochem Pharmacol; 2018 Sep; 155():380-392. PubMed ID: 30026023
[TBL] [Abstract][Full Text] [Related]
7. Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Robert J; Stukas S; Button E; Cheng WH; Lee M; Fan J; Wilkinson A; Kulic I; Wright SD; Wellington CL
Biochim Biophys Acta; 2016 May; 1862(5):1027-36. PubMed ID: 26454209
[TBL] [Abstract][Full Text] [Related]
8. ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy.
Montañola A; de Retana SF; López-Rueda A; Merino-Zamorano C; Penalba A; Fernández-Álvarez P; Rodríguez-Luna D; Malagelada A; Pujadas F; Montaner J; Hernández-Guillamon M
Neuromolecular Med; 2016 Mar; 18(1):99-108. PubMed ID: 26661731
[TBL] [Abstract][Full Text] [Related]
9. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.
Fryer JD; Simmons K; Parsadanian M; Bales KR; Paul SM; Sullivan PM; Holtzman DM
J Neurosci; 2005 Mar; 25(11):2803-10. PubMed ID: 15772340
[TBL] [Abstract][Full Text] [Related]
10. Intraventricular infusion of clusterin ameliorated cognition and pathology in Tg6799 model of Alzheimer's disease.
Qi XM; Wang C; Chu XK; Li G; Ma JF
BMC Neurosci; 2018 Jan; 19(1):2. PubMed ID: 29370749
[TBL] [Abstract][Full Text] [Related]
11. Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain.
Martin-Rehrmann MD; Hoe HS; Capuani EM; Rebeck GW
Neurotox Res; 2005; 7(3):231-42. PubMed ID: 15897157
[TBL] [Abstract][Full Text] [Related]
12. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
[TBL] [Abstract][Full Text] [Related]
13. Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways.
Wojtas AM; Kang SS; Olley BM; Gatherer M; Shinohara M; Lozano PA; Liu CC; Kurti A; Baker KE; Dickson DW; Yue M; Petrucelli L; Bu G; Carare RO; Fryer JD
Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6962-E6971. PubMed ID: 28701379
[TBL] [Abstract][Full Text] [Related]
14. Knockout of apolipoprotein A-I decreases parenchymal and vascular β-amyloid pathology in the Tg2576 mouse model of Alzheimer's disease.
Contu L; Carare RO; Hawkes CA
Neuropathol Appl Neurobiol; 2019 Dec; 45(7):698-714. PubMed ID: 31002190
[TBL] [Abstract][Full Text] [Related]
15. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.
Bell RD; Sagare AP; Friedman AE; Bedi GS; Holtzman DM; Deane R; Zlokovic BV
J Cereb Blood Flow Metab; 2007 May; 27(5):909-18. PubMed ID: 17077814
[TBL] [Abstract][Full Text] [Related]
16. The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice.
Rijal Upadhaya A; Scheibe F; Kosterin I; Abramowski D; Gerth J; Kumar S; Liebau S; Yamaguchi H; Walter J; Staufenbiel M; Thal DR
Acta Neuropathol Commun; 2013 Nov; 1(1):77. PubMed ID: 24252227
[TBL] [Abstract][Full Text] [Related]
17. Effects of an Aβ-antibody fragment on Aβ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides.
Montoliu-Gaya L; Mulder SD; Veerhuis R; Villegas S
PLoS One; 2017; 12(11):e0188191. PubMed ID: 29155887
[TBL] [Abstract][Full Text] [Related]
18. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease.
Kuo YM; Beach TG; Sue LI; Scott S; Layne KJ; Kokjohn TA; Kalback WM; Luehrs DC; Vishnivetskaya TA; Abramowski D; Sturchler-Pierrat C; Staufenbiel M; Weller RO; Roher AE
Mol Med; 2001 Sep; 7(9):609-18. PubMed ID: 11778650
[TBL] [Abstract][Full Text] [Related]
19. Association of candidate genetic variants and circulating levels of ApoE/ApoJ with common neuroimaging features of cerebral amyloid angiopathy.
Bonaterra-Pastra A; Benítez S; Pancorbo O; Rodríguez-Luna D; Vert C; Rovira A; Freijo MM; Tur S; Martínez-Zabaleta M; Cardona Portela P; Vera R; Lebrato-Hernández L; Arenillas JF; Pérez-Sánchez S; Domínguez-Mayoral A; Fàbregas JM; Mauri G; Montaner J; Sánchez-Quesada JL; Hernández-Guillamon M
Front Aging Neurosci; 2023; 15():1134399. PubMed ID: 37113571
[TBL] [Abstract][Full Text] [Related]
20. Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy.
Camacho J; Moliné T; Bonaterra-Pastra A; Ramón Y Cajal S; Martínez-Sáez E; Hernández-Guillamon M
Front Neurol; 2019; 10():187. PubMed ID: 30918495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
